Clinical Trials
AstraZeneca’s Imfinzi shows benefits in endometrial cancer trial
Treatment with the Imfinzi and Lynparza regimen caused a 32% reduction in the second progression or mortality risk.
Treatment with the Imfinzi and Lynparza regimen caused a 32% reduction in the second progression or mortality risk.